Granola Launches AI Workspace for Teams and Raises $43M Series B
LONDON--(BUSINESS WIRE)--Granola, the AI-powered notepad that combines your typed notes with AI transcriptions, today launches Granola 2.0. This major update transforms the company's popular AI meeting assistant into a powerful, intelligent workspace for teams. Every day, Granola transcribes and analyzes millions of minutes of conversation: collective knowledge which is now accessible and actionable across entire organizations.
"Since our launch a year ago, people have started referring to Granola as their 'second brain,'" said Christopher Pedregal, Co-Founder of Granola. "With Granola 2.0, we're bringing that power to your entire team, tapping into the most up-to-date, relevant data on what's happening in your company – the conversations your employees are having day in, day out."
Granola 2.0 and all its features are rolling out today. New users can download the desktop app and create their first shared folder in under a minute.
Beyond Meeting Notes: Harnessing Shared Context with AI
Granola has identified that the most valuable information in companies isn't found in static documents or wikis, but in the daily conversations happening across teams.
"Harnessing shared meeting context with AI will be a core tool of how effective teams work in the future," said Pedregal. "Our vision is to make Granola the place your team gets work done – a powerful, intelligent workspace sitting on top of living, up-to-date context of what's happening in your company."
With the launch of 2.0, Granola is now a collaborative workspace that transforms how teams capture, share, and leverage collective knowledge:
Shared Team Folders: Create dedicated spaces for Sales Calls, Customer Feedback, Hiring Loops, Weekly Syncs, and more, with folders that anyone on your team can access (even without a Granola account)
Chat with Folders: Query across an entire folder of meeting notes using best-in-class reasoning models, with AI delivering insights that cite specific meetings and transcripts as sources
Enterprise Collaboration: Business & Enterprise users can explore any public folder inside their domain—perfect for competitive intel, customer success, or onboarding new hires
Slack Integration: with a one-time connection to Slack, Granola can keep your whole team in the with concise summaries and a 'chat with this meeting' button posted to your chosen channel the moment the call ends
"With every call in one place, sales leaders can ask 'Why are we losing deals this quarter?,' product managers can investigate 'Which UX issues come up most often?,' and recruiters can understand 'Where do our interviews keep stalling?' — all answered instantly with source-linked citations," said Sam Stephenson, Co-Founder of Granola.
What's Next
The launch also coincides with the announcement that Granola has raised $43 million in Series B funding led by Nat Friedman and Daniel Gross from NFDG, with continued participation from existing investors Mike Mignano from Lightspeed Venture Partners and Nabeel Hyatt from Spark Capital. The company has also attracted investment from an impressive roster of angel investors, including Guillermo Rauch (Vercel), Amjad Masad (Replit), Tobi Lutke (Shopify), Karri Saarinen (Linear), Lenny Rachitsky (Lenny's Newsletter), Des Traynor (Intercom), Karim Atiyeh (Ramp), Zach Lloyd (Warp), Charlie Songhurst, Noah Weiss, Romain Huet, Nilan Peiris and Laura Modiano.
With this funding, Granola plans to continue expanding its team in London to accelerate product development. The company is focused on making Granola a tool that not only helps teams work better but think better.
About Granola
Granola was founded in March 2023 by Chris Pedregal and Sam Stephenson to change the way we work, with tools that understand us, anticipate our actions, and augment our abilities. In May 2023 they raised a $4.25M Seed round from Lightspeed Venture Partners, betaworks and FirstMinute, and raised a further $20M Series A in October 2024, led by Spark Capital, with participation from investors AI Grant, Lightspeed, Betaworks, Firstminute Capital, and others.
About the Founders
Chris Pedregal - https://www.linkedin.com/in/pedregal/
Chris studied Computer Science at Stanford before joining Google as a Product Manager, where he worked on Gmail, Search and Maps. In 2013 he quit to launch Socratic, an AI-powered tutor for high school students, which grew organically to 10+ million MAUs and won 'App of the Year' in 2017. In 2018, Socratic was acquired by Google, where it receives over four billion questions a year.
Sam Stephenson -
Sam studied graphic design at Falmouth before spending a few years in San Francisco at a design agency and an education non-profit. Along the way, he built his own startup connecting neighborhoods to local farmers, helped build an iOS app for Swim Smooth, designed interactive ski maps for Carv and helped an array of B2B companies with design and front end development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
CNET
15 hours ago
- CNET
Stop Putting Your Phone Face Up on the Table
Have you ever been phone snubbed? That's what happens when you're spending time with someone who seems more interested in their phone. Your friend might be sitting right across from you but when they're laughing at a video or meme that only they can see, it feels like they're a million miles away. I've been guilty of paying more attention to my screen than my companion and I feel bad about it afterward. There's nothing wrong with replying to an urgent Slack message or pulling up a funny TikTok to share. But I know I probably spend too much time staring at screens and a lot of that time is unhealthy doomscrolling. These days, when I'm not using my phone, I try to be more deliberate about keeping it out of sight and out of mind. If I do need to keep my phone at hand, I always have it face down. It could help save your phone battery I have a few reasons for making sure my phone screen is turned away. The first one is practical: Because my screen is face down and won't turn on for each notification, I can save a little bit of battery charge. A single notification won't mean the difference between my phone lasting the whole day or dying in the afternoon, but notifications can add up, especially if I've enabled them across all of my apps. If I'm in a lot of group chats, my screen might end up turning on dozens of times throughout the day (and that's on the low side because many teenagers have hundreds of notifications a day). It also shows that you pay attention Keeping my phone face down is also a good rule of social etiquette: If I'm hanging out with someone, I keep my screen hidden from view as a subtle way of showing that I won't be distracted by it. I don't want incoming notifications to light up my screen every few seconds, especially if I'm in a bar or other dimly lit setting. I want to keep my eyes on the person I'm talking to. "Eye contact is one of the most powerful forms of human connection. Neuroscience research indicates that when two people make direct eye contact, their brain activity begins to synchronize, supporting more effective communication and increasing empathy. This synchrony can be disrupted when attention shifts to a phone, even briefly," says Michelle Davis, clinical psychologist at Headspace. When I'm with the people I've chosen to spend time with, I want to be fully present with them. A sudden notification will tempt me to glance at, or worse, pick up my phone in the middle of a conversation. It minimizes your phone's presence I also have a more personal reason for keeping my phone face down and I suspect that other people have had this same thought: My phone takes up too much space in my life. I mean that quite literally. My phone is bigger than it needs to be. That's been especially true since I upgraded from my iPhone Mini to a "normal-sized" iPhone. Yes, I got a much needed boost in battery life but I also got a screen with more pixels to lure me into the next news headline or autoplaying Instagram reel. A small smartphone isn't something that really exists anymore. My phone is bigger and better at grabbing my attention. It competes against my friends and family, books and movies, the entire world outside of its 6-inch screen. It often wins. But there's still one small thing I can do to minimize its presence: I can keep the screen turned away from me whenever possible. It can sometimes feel like there's no escaping from my phone. Whether that ever changes, or phones evolve into a new form factor, I can't say. I can't control everything about my phone, but I can control whether the screen stares at me when I'm not staring at it.
Business Wire
a day ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
